查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
感染疾病临床检验分子诊断的全球市场:策略与趋势，各用途，各技术，各国预测 - 附执行顾问指南(2024年～2028年)
市场调查报告书
商品编码
1507970

感染疾病临床检验分子诊断的全球市场:策略与趋势，各用途，各技术，各国预测 - 附执行顾问指南(2024年～2028年)

Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets. Strategies and Trends. Forecasts by Application by Place and by Country. With Market Analysis & Executive Guides. 2024 to 2028
出版日期: | 出版商: Howe Sound Research | 英文 362 Pages | 商品交期: 最快1-2个工作天内

价格

传染病临床实验室分子诊断领域即将进一步成长。市场持续成长，但变得更加复杂和分散。传染病检测直接受益于生物技术，特别是基因组学的爆炸性发展。

本报告提供感染疾病临床检验分子诊断的全球市场调查，市场概要，以及各用途，场所，各国趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 市场指南

第2章 简介和市场定义

  • 市场定义
  • 调查手法
  • 观点:医疗保健和IVD产业
  • IVD产品的性质
  • 未来的IVD产品

第3章 感染疾病- 病原体的指南

  • 感染疾病病原体- 透视
  • 冠状病毒

第4章 产业概要

  • 市场进入组织
    • 学术研究机关
    • 诊断测试开发商
    • 仪器供应商
    • 药品·试剂厂商
    • 病理供应商
    • 独立型临床检验室
    • 公共的国立/地区研究所
    • 医院检验室
    • 临床检验室
    • 审核机关
    • 认证机关
  • 临床检验市场区隔
  • 产业结构

第5章 市场趋势

  • 成长促进因素
  • 成长限制要素
  • 测量，自动化，诊断趋势

第6章 感染疾病临床检验分子诊断:最近的趋势

第7章 主要企业

  • Abbott Laboratories
  • Agilent
  • Altona Diagnostics
  • Anitoa
  • Autonomous Medical Devices
  • Beckman Coulter Diagnostics(Danaher)
  • Becton, Dickinson and Company
  • BioGX
  • Biomatik
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc
  • Cepheid(Danaher)
  • Diasorin S.p.A.
  • DNAe
  • Flow Health
  • Global Access Diagnostics
  • Great Basin Scientific, Inc
  • Hologic
  • Novacyt
  • Novus Diagnostics
  • Oncimmune
  • One Codex
  • OraSure Technologies
  • Proof Diagnostics
  • Qiagen
  • QuidelOrtho
  • R-Biopharm AG
  • Response Biomedical
  • Revvity
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific
  • Vela Diagnostics
  • Veredus Laboratories
  • YD Diagnostics
  • Zhejiang Orient Gene Biotech

第8章 感染疾病临床检验分子诊断的全球市场

  • 全球市场概要，各国
  • 全球市场概要，各用途
  • 全球市场概要，各地区

第9章 感染疾病临床检验分子诊断的全球市场 - 各用途

  • 呼吸系统
  • 血液感染性病毒
  • 移植
  • 院内感染
  • 生殖健康
  • C19 Singleplex
  • 脑膜炎
  • 肠胃
  • 局部

第10章 感染疾病临床检验分子诊断的全球市场 - 各地区

  • 医院研究室
  • 门诊病人检验室
  • 照护现场
  • 其他的场所

第11章 附录

OVERVIEW:

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for further growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what's happening in this informative report. And find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations. Trends like ......

  • Multiplex testing
  • pathogen evolution and pandemics
  • biotechnology advances in genetics
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Situation Analysis

2 Introduction and Market Definition

  • 2.1 Market Definition
    • 2.1.1 Market Size
    • 2.1.2 Currency
    • 2.1.3 Years
  • 2.2 Methodology
    • 2.2.1 Methodology
    • 2.2.2 Sources
    • 2.2.3 Authors
  • 2.3 Perspective: Healthcare and the IVD Industry
    • 2.3.1 Global Healthcare Spending
    • 2.3.2 Spending on Diagnostics
    • 2.3.3 Important Role of Insurance for Diagnostics
  • 2.4 The Nature of the IVD Product
    • 2.4.1 Features Overview
    • 2.4.2 The Misunderstood Feature
    • 2.4.3 Regulation
    • 2.4.4 The Newest Feature
    • 2.4.5 The Oldest Feature
    • 2.4.6 All About Scope
    • 2.4.7 Why Turnaround is Becoming More Important
    • 2.4.8 The Role of Trust
  • 2.5 The IVD Product of the Future

3 Infectious Diseases - Guide to the Pathogens

  • 3.1 Infectious Disease Pathogens - The Big Picture
    • 3.1.1 Viruses
    • 3.1.2 Bacteria
    • 3.1.3 Fungi
    • 3.1.4 Parasites
    • 3.1.5 Prions
    • 3.1.6 Virulence
    • 3.1.7 Transmission
  • 3.2 The Coronavirus
    • 3.2.1 Severe acute respiratory syndrome (SARS)
    • 3.2.2 Middle East respiratory syndrome (MERS)
    • 3.2.3 COVID-19. The SARS CoV 2 Virus.
      • 3.2.3.1 Signs and symptoms
      • 3.2.3.2 Transmission
      • 3.2.3.3 Diagnosis
      • 3.2.3.4 Prevention
      • 3.2.3.5 Management
      • 3.2.3.6 Prognosis

4 Industry Overview

  • 4.1 Players in a Dynamic Market
    • 4.1.1 Academic Research Lab
    • 4.1.2 Diagnostic Test Developer
    • 4.1.3 Instrumentation Supplier
    • 4.1.4 Chemical/Reagent Supplier
    • 4.1.5 Pathology Supplier
    • 4.1.6 Independent Clinical Laboratory
    • 4.1.7 Public National/regional Laboratory
    • 4.1.8 Hospital Laboratory
    • 4.1.9 Physicians Office Lab (POLS)
    • 4.1.10 Audit Body
    • 4.1.11 Certification Body
  • 4.2 The Clinical Laboratory Market Segments
    • 4.2.1 Traditional Market Segmentation
    • 4.2.2 Laboratory Focus and Segmentation
    • 4.2.3 Segmenting the Syndromic Testing Market
  • 4.3 Industry Structure
    • 4.3.1 Hospital Testing Share
    • 4.3.2 Economies of Scale
    • 4.3.3 Hospital vs. Central Lab
    • 4.3.4 Physician Office Lab's
    • 4.3.5 Physician's and POCT

5 Market Trends

  • 5.1 Factors Driving Growth
    • 5.1.1 The Nucleic Acid Impact
    • 5.1.2 Population Dynamics
    • 5.1.3 The Developing World
    • 5.1.4 Decentralization
    • 5.1.5 Self Testing
    • 5.1.6 The Need for Speed
  • 5.2 Factors Limiting Growth
    • 5.2.1 Costs and Experience Curve Effects
    • 5.2.2 The Role of ID Prevalence
    • 5.2.3 Wellness
    • 5.2.4 The Impact of Living Standards
  • 5.3 Instrumentation, Automation and Diagnostic Trends
    • 5.3.1 Traditional Automation and Centralization
    • 5.3.2 The New Automation, Decentralization and Point Of Care
    • 5.3.3 Instruments Key to Market Share
    • 5.3.4 Bioinformatics Plays a Role
    • 5.3.5 PCR Takes Command
    • 5.3.6 Next Generation Sequencing Fuels a Revolution
    • 5.3.7 NGS Impact on Pricing
    • 5.3.8 Whole Genome Sequencing, A Brave New World
    • 5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment

6 Clinical Laboratory MDx Infectious Disease Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 Roche Respiratory Panel Receives FDA EUA
  • 6.3 Genetic Signatures Gets Approval for GI Parasite Panel
  • 6.4 Diasorin Expands Respiratory Panel
  • 6.5 BioMerieux Outlines MDx-Driven Growth
  • 6.6 T2 Biosystems Gets Extended T2Bacteria Panel
  • 6.7 Diasorin Aims to Deliver Updated Instruments, New Assays
  • 6.8 Oxford Nanopore Nabs Investment From BioMerieux
  • 6.9 Day Zero Diagnostics Closes Financing Round
  • 6.10 Spindiag Seeks Investors for Rapid PCR System
  • 6.11 Sorrento Therapeutics Nabs Contract for Dx Platform
  • 6.12 Kephera Planning Menu of Infectious Disease Tests
  • 6.13 Oxford Nanopore and BioMerieux to Develop IDDx
  • 6.14 SD Biosensor Eyes Global Expansion
  • 6.15 Selux Dx Next Gen Phenotyping Gets FDA Clearance
  • 6.16 Takara Developing High-Throughput Multiplex Panels
  • 6.17 BioGX Debuts New Point-of-Care Molecular Testing System
  • 6.18 Nanopath MDx Platform Providing 15-Minute Results
  • 6.19 ProtonDx Commercializing Rapid MDx Instrument
  • 6.20 Siemens Healthineers to Develop Next-Gen, High-Throughput MDx Platform
  • 6.21 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays
  • 6.22 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS
  • 6.23 Accelerate Diagnostics Anticipates Growth
  • 6.24 Growth of Decentralized Testing Expected to Continue
  • 6.25 Lumos Diagnostics Expanding Test Portfolio
  • 6.26 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens
  • 6.27 CareDx, IDbyDNA Develop Infectious Disease Dx for Transplant Patients

7 Key Companies

  • 7.1 Abbott Laboratories
  • 7.2 Agilent
  • 7.3 Altona Diagnostics
  • 7.4 Anitoa
  • 7.5 Autonomous Medical Devices
  • 7.6 Beckman Coulter Diagnostics (Danaher)
  • 7.7 Becton, Dickinson and Company
  • 7.8 BioGX
  • 7.9 Biomatik
  • 7.10 bioMerieux Diagnostics
  • 7.11 Bio-Rad Laboratories, Inc
  • 7.12 Cepheid (Danaher)
  • 7.13 Diasorin S.p.A.
  • 7.14 DNAe
  • 7.15 Flow Health
  • 7.16 Global Access Diagnostics
  • 7.17 Great Basin Scientific, Inc
  • 7.18 Hologic
  • 7.19 Novacyt
  • 7.20 Novus Diagnostics
  • 7.21 Oncimmune
  • 7.22 One Codex
  • 7.23 OraSure Technologies
  • 7.24 Proof Diagnostics
  • 7.25 Qiagen
  • 7.26 QuidelOrtho
  • 7.27 R-Biopharm AG
  • 7.28 Response Biomedical
  • 7.29 Revvity
  • 7.30 Roche Diagnostics
  • 7.31 Siemens Healthineers
  • 7.32 Thermo Fisher Scientific
  • 7.33 Vela Diagnostics
  • 7.34 Veredus Laboratories
  • 7.35 YD Diagnostics
  • 7.36 Zhejiang Orient Gene Biotech

8 The Global Market for Clinical Laboratory MDx Infectious Disease

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart-Global Market by Country
  • 8.2 Global Market by Application-Overview
    • 8.2.1 Table - Global Market by Application
    • 8.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Application - Base Year
    • 8.2.4 Chart - Global Market by Application - End Year
    • 8.2.5 Chart - Global Market by Application - Share by Year
    • 8.2.6 Chart - Global Market by Application - Segments Growth
  • 8.3 Global Market by Place-Overview
    • 8.3.1 Table - Global Market by Place
    • 8.3.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Place - Base Year
    • 8.3.4 Chart - Global Market by Place - End Year
    • 8.3.5 Chart - Global Market by Place - Share by Year
    • 8.3.6 Chart - Global Market by Place - Segments Growth

9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application

  • 9.1 Respiratory
    • 9.1.1 Table Respiratory - by Country
    • 9.1.2 Chart-Respiratory Growth
  • 9.2 Blood Borne Virus
    • 9.2.1 Table Blood Borne Virus - by Country
    • 9.2.2 Chart-Blood Borne Virus Growth
  • 9.3 Transplant
    • 9.3.1 Table Transplant - by Country
    • 9.3.2 Chart-Transplant Growth
  • 9.4 Hospital Acquired Infections
    • 9.4.1 Table Hospital Acquired Infections - by Country
    • 9.4.2 Chart-Hospital Acquired Infections Growth
  • 9.5 Reproductive Health
    • 9.5.1 Table Reproductive Health - by Country
    • 9.5.2 Chart - Reproductive Health Growth
  • 9.6 C19 Singleplex
    • 9.6.1 Table C19 Singleplex - by Country
    • 9.6.2 Chart - C19 Singleplex Growth
  • 9.7 Meningitis
    • 9.7.1 Table Meningitis - by Country
    • 9.7.2 Chart-Meningitis Growth
  • 9.8 Gastrointestinal
    • 9.8.1 Table Gastrointestinal - by Country
    • 9.8.2 Chart-Gastrointestinal Growth
  • 9.9 Tropical
    • 9.9.1 Table Tropical - by Country
    • 9.9.2 Chart-Tropical Growth

10 Global Clinical Laboratory MDx Infectious Disease Markets - By Place

  • 10.1 Hospital Lab
    • 10.1.1 Table Hospital Lab - by Country
    • 10.1.2 Chart - Hospital Lab Growth
  • 10.2 Outpatient Lab
    • 10.2.1 Table Outpatient Lab - by Country
    • 10.2.2 Chart - Outpatient Lab Growth
  • 10.3 Point of Care
    • 10.3.1 Table Point of Care - by Country
    • 10.3.2 Chart - Point of Care Growth
  • 10.4 Other Place
    • 10.4.1 Table Other Place - by Country
    • 10.4.2 Chart - Other Place Growth

11 Appendices

  • 11.1 Growth of Approved IVD Test Menu
  • 11.2 Growth of Approved Average IVD Test Fee
  • 11.3 The Most Used IVD Assays
  • 11.4 The Highest Grossing Assays
  • 11.5 Laboratory Fees Schedule

Table of Tables

  • Table 1 Key IVD Features
  • Table 2 Features in the Future
  • Table 3 Viral Pathogens and Families
  • Table 4 Characteristics of Coronavirus Pandemic Infections
  • Table 5 COVID-19 Symptoms
  • Table 6 Market Players by Type
  • Table 7 Clinical Laboratory Departments and Segments
  • Table 8 Laboratory Management Focus - Different Approaches
  • Table 9 Key Segmentation Variables Going Forward
  • Table 10 Possible Market Segments of Syndromic Multiplex Market
  • Table 11 Five Factors Driving Growth
  • Table 12 Four Factors Limiting Growth
  • Table 13 Seven Key Diagnostic Laboratory Technology Trends
  • Table 14-Global Market by Region
  • Table 15 Global Market by Application
  • Table 16 Global Market by Place
  • Table 17 Respiratory by Country
  • Table 18 Blood Borne Virus by Country
  • Table 19 Transplant by Country
  • Table 20 Hospital Acquired Infections by Country
  • Table 21 Reproductive Health by Country
  • Table 22 C19 Singleplex by Country
  • Table 23 Meningitis by Country
  • Table 24 Gastrointestinal by Country
  • Table 25 Tropical by Country
  • Table 26 Hospital Lab by Country
  • Table 27 Outpatient Lab by Country
  • Table 28 Point of Care by Country
  • Table 29 Other Place by Country
  • Table 30 The Most Common Assays
  • Table 31 Largest Revenue Assays
  • Table 32 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Global Health Care Spending Per Capita
  • Figure 2 The Lab Test Pie
  • Figure 3 Structure of a Typical Virus
  • Figure 4 Mycobacterium Tuberculosis
  • FIGURE 5 STRUCTURE OF CORONAVIRUSES
  • Figure 6 The Road to Diagnostics
  • Figure 7 The Changing Age of The World's Population
  • Figure 8 Health Care Consumption by Age
  • Figure 9 Cancer Incidence-Age at Diagnosis
  • Figure 10 Percentage of World Population Over 65
  • Figure 11 Chart Infectious Disease Decline
  • Figure 12 Centralized vs. Decentralized Laboratory Service
  • Figure 13 A Highly Multiplexed Syndromic Testing Unit
  • Figure 14 The Real Cost to Sequence the Human Genome
  • Figure 15 The Codevelopment Process
  • Figure 16 Global Market Share Chart
  • Figure 17 Global Market by Application-Base vs. Final
  • Figure 18 Global Market by Application Base Year
  • Figure 19 Global Market by Application End Year
  • Figure 20 Application Share by Year
  • Figure 21 Application Segments Growth
  • Figure 17 Global Market by Place-Base vs. Final
  • Figure 18 Global Market by Place Base Year
  • Figure 19 Global Market by Place End Year
  • Figure 20 Place Share by Year
  • Figure 21 Place Segments Growth
  • Figure 22 Respiratory Growth
  • Figure 23 Blood Borne Virus Diagnostics Growth
  • Figure 24 Transplant Growth
  • Figure 25 Hospital Acquired Infections Growth
  • Figure 26 Reproductive Health Growth
  • Figure 27 C19 Singleplex Growth
  • Figure 28 Meningitis Growth
  • Figure 28 Gastrointestinal Growth
  • Figure 28 Tropical Growth
  • Figure 22 Hospital Lab Growth
  • Figure 23 Outpatient Lab Growth
  • Figure 24 Point of Care Growth
  • Figure 25 Other Place Growth
  • Figure 29 IVD Test Menu Growth
  • Figure 30 IVD Test Average Fees - A Ten Year View